Conflict of interest
This article was originally published in The Tan Sheet
Executive Summary
NEJM revises conflict of interest policies for review articles, editorials that do not contain new data. New policy substitutes phrase "authors...will not have any financial interest in a company (or its competitor) that makes a product discussed in the article" with "not have any significant financial interest." Addition of word significant "acknowledges that not all financial associations are the same," editors write in June 13 issue. Significant means a $10,000 annual financial interest, the same de minimis level as that set by NIH, Association of American Medical Colleges. Journal's policy on research grants continues to require that authors cannot have major research support, funding from relevant companies...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.